 Lipopeptides
"Lipopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds consisting of a short peptide chain conjugated with an acyl chain.
| Descriptor ID |
D055666
|
| MeSH Number(s) |
D10.477 D12.644.365
|
| Concept/Terms |
Anionic Lipopeptides- Anionic Lipopeptides
- Lipopeptides, Anionic
- Anionic Lipopeptide
- Lipopeptide, Anionic
Cationic Lipopeptides- Cationic Lipopeptides
- Lipopeptides, Cationic
- Cationic Lipopeptide
- Lipopeptide, Cationic
|
Below are MeSH descriptors whose meaning is more general than "Lipopeptides".
Below are MeSH descriptors whose meaning is more specific than "Lipopeptides".
This graph shows the total number of publications written about "Lipopeptides" by people in this website by year, and whether "Lipopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2011 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lipopeptides" by people in Profiles.
-
Endres BT, Bassères E, Alam MJ, Garey KW. Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
-
Endres BT, Bassères E, Khaleduzzaman M, Alam MJ, Chesnel L, Garey KW. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 Jun; 60(6):3519-23.
-
Beyda ND, Liao G, Endres BT, Lewis RE, Garey KW. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
-
Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
-
Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep; 66(9):2146-51.
-
Lewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. J Antimicrob Chemother. 2011 Jun; 66(6):1324-31.
-
Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother. 2005 Dec; 49(12):5146-8.
-
Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis. 2005 Aug 01; 41(3):e27-8.
-
Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004 Oct 15; 190(8):1464-71.
-
Hsue G, Napier JT, Prince RA, Chi J, Hospenthal DR. Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother. 2004 Jul; 54(1):292-4.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|